Compare PICS & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PICS | HRMY |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | N/A | 2020 |
| Metric | PICS | HRMY |
|---|---|---|
| Price | $13.08 | $29.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 10 |
| Target Price | $22.00 | ★ $46.70 |
| AVG Volume (30 Days) | ★ 702.6K | 605.9K |
| Earning Date | 05-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 2.71 |
| Revenue | N/A | ★ $868,453,000.00 |
| Revenue This Year | $29.68 | $19.75 |
| Revenue Next Year | $39.06 | $12.88 |
| P/E Ratio | $29.44 | ★ $10.72 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $9.88 | $25.52 |
| 52 Week High | $18.49 | $40.87 |
| Indicator | PICS | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 53.44 | 56.76 |
| Support Level | $10.09 | $25.92 |
| Resistance Level | $15.33 | $30.96 |
| Average True Range (ATR) | 0.79 | 0.82 |
| MACD | 0.37 | 0.42 |
| Stochastic Oscillator | 89.54 | 91.72 |
PicS NV is a digital payments company. The company operates a peer-to-peer (P2P) transfer platform that enables individuals to send money via mobile devices. It provides digital wallets, instant payments (Pix), P2P transfers, credit cards, loans, investments, insurance, and SMB payment solutions. The company has four reportable segments: Consumer Banking, Small and Medium-Sized Businesses, Audiences and Ecosystem Integration, and Institutional. The majority of the company's revenue is derived from the Consumer Banking segment, which generates revenue from various transaction activities occurring in the digital wallet, such as Pix, peer-to-peer (P2P) transfers, and bill payments.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.